Nihar Desai, Hematology Chief Fellow at Princess Margaret Cancer Centre, shared on LinkedIn:
“Happy to share our views on Letermovir strategy after D+100. In this piece, we discuss the evidence supporting extended primary prophylaxis vs. secondary prophylaxis and its clinical implications.”
Title: Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation
Authors: Nihar Desai, Gonzalo Bentolila, Jonas Mattsson
Other articles about Hematology on OncoDaily.